XUP Stock Chart & Stats
€14.46
€0.00(0.00%)
At close: 4:00 PM EDT
€14.46
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€3.42 - €14.92
Previous CloseN/A
Volume0.00
Average Volume (3M)389.00
Market Cap
€406.17M
Enterprise Value€595.85M
Total Cash (Recent Filing)€113.82M
Total Debt (Recent Filing)€179.28M
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Apr 08, 2027EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.04
Shares Outstanding50,099,620
10 Day Avg. Volume305
30 Day Avg. Volume389
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-11.11
Price to Sales (P/S)4.01
P/FCF Ratio-9.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€15.00Price Target Upside3.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.3
Revenue Forecast (FY)€86.71M
Bulls Say, Bears Say
Bulls Say
Strong 2025 Revenue GrowthThe sharp 2025 revenue rebound indicates that Genfit can generate meaningful transaction or development-related income when pipeline and partnership activity progress. If this growth is supported by additional milestones or collaborations, it can strengthen funding capacity and validate the company’s strategic focus.
Specialized Liver-Disease PlatformConcentration on metabolic and liver diseases gives Genfit a clearly defined scientific and commercial identity rather than a broad, unfocused pipeline. Its diagnostic and biomarker capabilities may support differentiated development programs and create multiple opportunities for future partnerships.
Partnership-Based MonetizationA partnership- and transaction-based model can monetize clinical assets without relying solely on recurring product sales or fully funding every commercialization stage internally. Successful development milestones or licensing transactions could provide non-linear revenue opportunities as programs advance.
Bears Say
Return To Large LossesThe reversal from profit to large operating and net losses shows that earnings remain highly dependent on uneven development or transaction activity. Persistent volatility reduces confidence in durable profitability and may make future planning, reinvestment, and external funding more difficult.
Renewed Cash BurnNegative operating and free cash flow indicate that current activities are not consistently self-funding. The return to cash burn, alongside several earlier years of sizable negative cash flow, increases the likelihood that Genfit will need additional financing or asset transactions to sustain development.
Negative Equity And Higher DebtNegative shareholders’ equity and materially higher debt represent a substantial weakening of financial resilience. This reduces balance-sheet flexibility, increases pressure to manage funding carefully, and leaves less capacity to absorb continued losses while advancing clinical and diagnostic programs.
Genfit News
XUP FAQ
What was Genfit SA’s price range in the past 12 months?
Genfit SA lowest stock price was €3.42 and its highest was €14.92 in the past 12 months.
What is Genfit SA’s market cap?
Genfit SA’s market cap is €406.17M.
When is Genfit SA’s upcoming earnings report date?
Genfit SA’s upcoming earnings report date is Apr 08, 2027 which is in 173 days.
How were Genfit SA’s earnings last quarter?
Genfit SA released its earnings results on Sep 28, 2026. The company reported -€0.2 earnings per share for the quarter, missing the consensus estimate of -€0.16 by -€0.04.
Is Genfit SA overvalued?
According to Wall Street analysts Genfit SA’s price is currently Undervalued.
Does Genfit SA pay dividends?
Genfit SA does not currently pay dividends.
What is Genfit SA’s EPS estimate?
Genfit SA’s EPS estimate is -0.37.
How many shares outstanding does Genfit SA have?
Genfit SA has 50,099,620 shares outstanding.
What happened to Genfit SA’s price movement after its last earnings report?
Genfit SA reported an EPS of -€0.2 in its last earnings report, missing expectations of -€0.16. Following the earnings report the stock price went down -1.441%.
Which hedge fund is a major shareholder of Genfit SA?
Currently, no hedge funds are holding shares in DE:XUP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Genfit SA
Genfit S.A. operates as a biopharmaceutical enterprise, concentrating its efforts on discovering and developing both therapeutic candidates and diagnostic solutions for metabolic and liver-related ailments. Its current pipeline includes Elafibranor, which is progressing through Phase 3 clinical trials for the treatment of primary biliary cholangitis (PBC). The firm is additionally engaged in advancing the NIS4 technology, designed for the accurate diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. Other investigational treatments comprise GNS561, currently in Phase 1b/2 trials for cholangiocarcinoma (CCA), and Nitazoxanide, undergoing Phase 1 evaluation for acute-on-chronic liver failure. Genfit has established key partnerships, notably a licensing agreement with Labcorp for the commercialization of NASHnext, a molecular diagnostic test leveraging blood samples. Furthermore, it collaborates with Genoscience Pharma on the development and market launch of the experimental CCA therapy, GNS561. Established in 1999, Genfit S.A. maintains its headquarters in Loos, France.
XUP Stock 12 Month Forecast
Average Price Target
€15.00
▲(3.73% Upside)